Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer: A Southwest Oncology Group study

✍ Scribed by Giuseppe Colucci

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 71 KB
• Volume: 77
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19960301)77:5<1002::aid-cncr29>3.0.co;2-6

✦ Synopsis

n the article published in Cancer entitled "Phase I1 study of 5-fluoro-I uracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study,"' the authors erroneously quoted the results of our study and we request a correction.

In the results of our preliminary study, published as an abstract in Annals of OnCOlOW/,' our response rate (CR + PR) for advanced gastric cancer patients treated with folinic acid-5-fluorouracil (PA-FU) was 41%, not the 59% response rate published in Cancer. It is obvious that stable disease was also considered as a response in our study, however the authors of the Cancer article did not consider stable disease in their own response rate. At any rate, 59% is a completely unrealistic response to this treatment and should be corrected. In the final results of this study published in American Journal of Clinical Oncology,3 in fact, the objective response rate was 29% for the FA-FU arm versus 42% for the folinic acid-5-fluorouracil-4-epidoxorobicin (FA-FU-EPI) arm. We await a published correction of this error.